Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Targeted Therapies in Asthma: Update Bulletin [July 2016]

Product Code:
596200474
Publication Date:
July 2016
Format:
PDF
Price:
£1,140

This edition presents key opinion leader (KOL) views on recent developments in the asthma market. Topics covered include the latest clinical trial data presented by AstraZeneca and Teva at the 2016 American Thoracic Society International Conference in San Francisco, California (ATS 2016) with regard to their anti-interleukin-5 (IL-5) monoclonal antibodies (mAb) benralizumab and reslizumab, respectively. KOL’s views on the potential for a biosimilar version of Xolair (omalizumab), currently in Phase II/III development by Sorrento Therapeutics, are also explored. 

Most pressing questions answered:

  • AstraZeneca reports positive outcomes with benralizumab from the Phase III SIROCCO and CALIMA trials, but how well has this data been received amongst prescribers?
  • Can benralizumab, the third anti-IL-5 mAb to market, differentiate from its direct competitors?
  • Teva reports positive outcomes with Cinqair (reslizumab), but exactly how important is the reported reduction in patients’ systemic corticosteroid burden to prescribers?
  • Does reslizumab’s intravenous route of administration render this product less competitive than other anti-IL-5 therapies?
  • What impact will the anti-IL-5 mAbs have on the treatment of severe asthma?
  • What barriers are there to Sorrento Therapeutics’ biosimilar omalizumab gaining a foothold in the asthma market?



customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved